Suppr超能文献

相似文献

1
Tuberous sclerosis complex-associated CNS abnormalities depend on hyperactivation of mTORC1 and Akt.
J Clin Invest. 2018 Apr 2;128(4):1688-1706. doi: 10.1172/JCI96342. Epub 2018 Mar 12.
5
TFEB activation restores migration ability to Tsc1-deficient adult neural stem/progenitor cells.
Hum Mol Genet. 2017 Sep 1;26(17):3303-3312. doi: 10.1093/hmg/ddx214.
6
A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.
Int J Dev Neurosci. 2013 Nov;31(7):667-78. doi: 10.1016/j.ijdevneu.2013.02.008. Epub 2013 Feb 26.
7
Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA).
Expert Opin Pharmacother. 2020 Aug;21(11):1329-1336. doi: 10.1080/14656566.2020.1751124. Epub 2020 Apr 27.

引用本文的文献

1
A bitopic mTORC inhibitor reverses phenotypes in a tuberous sclerosis complex model.
Sci Rep. 2025 Jul 1;15(1):20367. doi: 10.1038/s41598-025-08345-z.
2
TSC-mTORC1 Pathway in Postnatal V-SVZ Neurodevelopment.
Biomolecules. 2025 Apr 12;15(4):573. doi: 10.3390/biom15040573.
3
Unraveling the function of TSC1-TSC2 complex: implications for stem cell fate.
Stem Cell Res Ther. 2025 Feb 4;16(1):38. doi: 10.1186/s13287-025-04170-3.
4
A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence.
Front Immunol. 2024 Sep 26;15:1425988. doi: 10.3389/fimmu.2024.1425988. eCollection 2024.
5
coordinates neuroprogenitor differentiation.
iScience. 2023 Nov 14;26(12):108442. doi: 10.1016/j.isci.2023.108442. eCollection 2023 Dec 15.
6
Targeting mTOR Pathway in PTEN Deleted Newly Isolated Chordoma Cell Line.
J Pers Med. 2023 Feb 27;13(3):425. doi: 10.3390/jpm13030425.
8
Activation of Rictor/mTORC2 signaling acts as a pivotal strategy to protect against sensorineural hearing loss.
Proc Natl Acad Sci U S A. 2022 Mar 8;119(10):e2107357119. doi: 10.1073/pnas.2107357119. Epub 2022 Mar 1.
9
Isolation and Culture of Neural Stem/Progenitor Cells from the Postnatal Periventricular Region.
Methods Mol Biol. 2022;2389:11-31. doi: 10.1007/978-1-0716-1783-0_2.
10
Identification of a Kupffer cell subset capable of reverting the T cell dysfunction induced by hepatocellular priming.
Immunity. 2021 Sep 14;54(9):2089-2100.e8. doi: 10.1016/j.immuni.2021.05.005. Epub 2021 Aug 31.

本文引用的文献

1
The genomic landscape of tuberous sclerosis complex.
Nat Commun. 2017 Jun 15;8:15816. doi: 10.1038/ncomms15816.
2
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations.
Cancer Cell. 2017 Jun 12;31(6):820-832.e3. doi: 10.1016/j.ccell.2017.04.013. Epub 2017 May 18.
3
Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex.
J Cancer. 2017 Feb 11;8(4):555-562. doi: 10.7150/jca.17205. eCollection 2017.
5
Genetics of tuberous sclerosis complex: implications for clinical practice.
Appl Clin Genet. 2016 Dec 21;10:1-8. doi: 10.2147/TACG.S90262. eCollection 2017.
6
Induction of Expansion and Folding in Human Cerebral Organoids.
Cell Stem Cell. 2017 Mar 2;20(3):385-396.e3. doi: 10.1016/j.stem.2016.11.017. Epub 2016 Dec 29.
8
PTEN Signaling in the Postnatal Perivascular Progenitor Niche Drives Medulloblastoma Formation.
Cancer Res. 2017 Jan 1;77(1):123-133. doi: 10.1158/0008-5472.CAN-16-1991. Epub 2016 Nov 4.
9
The mTOR signalling cascade: paving new roads to cure neurological disease.
Nat Rev Neurol. 2016 Jul;12(7):379-92. doi: 10.1038/nrneurol.2016.81. Epub 2016 Jun 24.
10
mTORC1 Inhibition Corrects Neurodevelopmental and Synaptic Alterations in a Human Stem Cell Model of Tuberous Sclerosis.
Cell Rep. 2016 Apr 5;15(1):86-95. doi: 10.1016/j.celrep.2016.02.090. Epub 2016 Mar 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验